TNOX Tanox (MM)

HOUSTON, April 17 /PRNewswire-FirstCall/ -- Tanox, Inc. (NASDAQ:TNOX) will deliver company presentations in May at Deutsche Bank's Health Care Conference in Boston and the Bank of America Health Care Conference in Las Vegas. Tanox President and Chief Executive Officer Danong Chen will deliver a company update at the Deutsche Bank conference May 3 at 1 p.m., EDT. Vice President of Finance Greg Guidroz and Dr. Stanley Lewis, medical director, will present at the Bank of America conference May 16 at 6:20 p.m., EDT. Live webcasts of the presentations will be accessible from the Investor Relations section on the company's Web site at http://www.tanox.com/ . Presentation slides will be available on the site following the live address at each conference. About Tanox, Inc. Tanox is a biotechnology company specializing in the discovery and development of monoclonal antibodies. The company develops innovative biotherapeutics for the treatment of immune-mediated diseases, inflammation, infectious disease and cancer. Tanox's lead investigational therapy, TNX-355, is a viral-entry inhibitor antibody to treat HIV/AIDS. TNX-355 has shown significant antiviral activity in Phase 2 clinical testing. Tanox's first- approved drug, Xolair(R) (omalizumab), is the first antibody approved to treat moderate-to-severe confirmed allergic asthma. Xolair was developed in collaboration with Genentech, Inc. and Novartis Pharma AG and is approved for marketing in the United States, Canada and major European countries. Tanox is based in Houston and has a manufacturing facility in San Diego. Additional corporate information is available at http://www.tanox.com/ . http://www.newscom.com/cgi-bin/prnh/20050207/TNOXLOGO DATASOURCE: Tanox, Inc. CONTACT: Steve Sievert of Tanox, Inc., +1-713-578-4211, or Web site: http://www.tanox.com/

Copyright